Congrats. Evolus (EOLS) is the first company to win FDA approval for a neurotoxin that is considered biosimilar to branded Botox for the …
Investors in Catalyst Pharmaceuticals (NASDAQ:CPRX) have been waiting for two-and-a-half years since its marketing application was originally submitted to see the company’s flagship candidate …
Canaccord’s John Newman finds SGYP’s Trulance commercial potential enticing down the line against its competitors.
Now that SGYP has won over FDA approval in a new indication (IBS-C), did the biotech company’s competitive edge just get sharper?
Cowen’s Phil Nadeau looks for “rapid adoption” in La Jolla’s Giapreza’s approved wider indication to hike up blood pressure in refractory patients.
Cowen believes Dynavax has an asset on its hands that fulfills a valuable unmet need.
Dynavax Technologies Corporation (NASDAQ:DVAX) has won U.S.
Keryx Biopharmaceuticals (NASDAQ:KERX) announced that the FDA has approved Auryxia for an additional indication. The approval is for the treatment of iron deficiency anemia in …
Cowen weighs in on encouraging ANS Phase III data expecting green light for KERX’s ferric citrate tablets.
Louise Chen notes that under OPK’s agreement with Tesaro, the approval of Varubi IV is a huge win.
